Summary Little is known of the molecular-genetic changes in carcinoma of the pancreas (CaP). In order to investigate the allele loss, or loss of heterozygosity (LOH), in CaP, we studied 13 patients with exocrine CaP and two with endocrine CaP using restriction fragment length polymorphism analysis. Twenty probes assigned to chromosomes 1, 5, 7, 9, 11, 12, 13, 14, 16, 17 and 18 were used. The frequency of LOH, or fractional allele loss (FAL), was found in two endocrine tumours to be 0.333 and 0.455 respectively; and FAL in 13 oxocrine tumours ranged from 0 to 0.25. Allele loss was shown in both exocrine and endocrine tumours by the probes Lambda MS1 at lp33-35, and pMS51 at llql3. Probes for other chromosomes have as yet shown no consistent LOH. In conclusion, the study showed LOH on chromosomes 1 and 11 in both exocrine and endocrine CaP.
There are few reports about allele loss in CaP, in contrast to the comprehensive studies of other common malignancies, such as those in breast (Devillee et al., 1989) , colorectum (Vogelstein et al., 1989) , liver (Fujimori et al., 1991) and lung (Kok et al., 1987) . Allele losses on chromosome 11 in both sporadic and familial pancreatic endocrine tumours, related to multiple endocrine neoplasia type 1 (MEN 1), have been reported (Bale et al., 1991; Teh et al., 1990) . There have been preliminary reports of allele loss on 5q for exocrine CaP (Michelassi et al., 1989; Westbrook et al., 1990) . It is of interest to know whether allele loss on chromosome 11 or other chromosomes also occurs in exocrine CaP, and whether there is any association between allele loss and clinical course in patients with CaP. Here we report a study of allele loss in CaP by screening with 20 RFLP markers, and the relationship between fractional allele loss and clinical parameters.
Materials and methods

Patients and biopsies
Fifteen patients with carcinoma of the pancreas were studied, including two with endocrine CaP and 13 with exocrine CaP. Of the 13 with exocrine CaP 12 had tumours of the head of pancreas while the remaining one had a tumour of the ampulla of vater. All underwent resection of their tumours (either by partial or total pancreatectomy) except one patient with peritoneal secondaries that had palliative bypass (hepaticojejunostomy and gastrojejunostomy). Of the 13 patients with exocrine CaP, four had their tumours localised to the pancreas while the other nine had metastases in local lymph nodes or extension of their tumours in adjacent portal vein. Judged by the operating surgeons, seven patients had small tumours that were resected radically while the remaining six had large tumours or late diseases such that their surgical procedures should be considered palliative. All patients, if applicable, were followed-up for detection of post-operation recurrence. The data were available until 1 year after tumour resection.
Surgical biopsies from the tumoral and non-tumoral pancreas tissues were snap frozen in liquid nitrogen at the time of operation. Lymphocytes from peripheral blood obtained pre-operatively were also used as a source of normal DNA. Tissue was stored at -70'C until DNA extraction. None of the patients received chemotherapy or radiotherapy prior to surgery and tumour samples were examined histologically to confirm the type of tumour present and the degree of differentiation of tumour cells.
DNA extraction and analysis DNA was prepared from blood and tissue samples by standard methods (Sambrook et al., 1989) . Southern analyses were done as previously described (Ding et al., 1991) . The 20 RFLP probes for chromosomes 1, 5, 7, 9, 11, 12, 13, 14, 16, 17 and 18 and the appropriate restriction enzymes are listed in Table I . If two alleles appeared as two separate bands in the resultant autoradiograph of the constitutional DNA, the patient was considered 'informative', or heterozygous, for the particular marker. Complete deletion or great loss of intensity of one band in the tumour DNA indicated an allele loss, or an LOH. The fractional allele loss (FAL) was defined in a tumour as the number of chromosomal arms on which allelic loss was observed divided by the number of chromosomal arms for which allelic markers were informative in the patient's normal cells (Vogelstein et al., 1989) .
Statistical analysis
The significance of the relationship between frequency of allele loss and clinical parameters was checked by the Fisher's exact test (Bland, 1987 (Table II) .
The possible relationship between allele loss and some clinical parameters in exocrine CaP was analysed (Table III) . Of seven small tumours (<3 cm), one had an allele loss, while out of six large tumours (>3 cm) five showed LOH (P <0.05). Allele loss was shown in four out of five tumours JJ informative patient with endocrine CaP in our study also had ,A11mLa lr-o ;* +U;e -v;r Tin+,mraLt;1nMlx thkaro xsae T rIT-ehkr%unn ing that breakpoint in a second (Johansson et al., 1991) . XMS 1
Allele loss at lp33-35 was shown by the probe Lambda MSI ii in this study in both exocrine (three out of 12 informative rcacle TAih1 T) and Pneocrine ()2/) Tahle i) CaP which mav indicate a possible tumour suppressor gene located there for both types of CaP, but as this region is frequently involved in advanced cancers of other types, its loss may be related to tumour progression (reviewed in Sager, 1989) . More cases are needed to confirm the preliminary finding. It is of interest that allele loss also occurred on chromosome lq in both endocrine cases, which may suggest that loss of genetic material in this region may be of importance for endocrine tumours.
Recently, loss or mutation of the p53 tumour suppressor B T gene at 17p 13 has been seen at very high frequency in several pMS 51 common human malignancies (Stanbridge, 1990) . A recent study in exocrine CaP also showed high frequency of overSouthern hybridisaexpression of mutant forms of p53 by immunohistochemistry and and of point mutations of the p53 gene by direct sequencing A, N = Non-tumour of genomic DNA (Barton et al., 1991 (Horowitz et al., 1990) 
